Pay in 4 interest-free payments of $5.54 Learn more
Ships within 48 hours · Estimated delivery Aug 30 - Sep 4
Leave at least 10-15 minutes between applying different serums or treatments
Heres what the clinical evidence shows: Study Scope: 900+ participants across 6 randomized, double-blind, placebo-controlled trials Safety Profile: Indistinguishable from placebo in tolerability assessments Serious Events: Zero serious adverse events attributed to AOD-9604 Withdrawals: No treatment-related discontinuations in any trial Common Effects: Mild headache and minor GI symptoms at rates similar to placebo IGF-1 Impact: No effect on insulin-like growth factor-1 levels Metabolic Safety: No negative impact on glucose metabolism or insulin sensitivity Immunogenicity: Zero participants developed anti-AOD9604 antibodies The following analysis provides complete details on the clinical trial evidence supporting AOD-9604s favorable safety profile
GHK-Cu glycyl-L-histidyl-L-lysine bound to copper was discovered in 1973 by Loren Pickart, who isolated it from human plasma
GHK-Cu (targeted by GHK-Cu Cream) GHK-Cu plasma levels drop to approximately one-third of youthful levels by age 60
US$ 25.93
US$ 20.80
-1.jpg&w=3840&q=75)
US$ 29.06
